Results of a surgically derived nomogram to predict gleason score upgrading applied to a cohort of patients with "favorable-risk" prostate cancer treated with permanent seed brachytherapy

Urology

Volumn 80, Issue 3, 2012, Pages 649-655

  Bowes, David ^a   Crook, Juanita M ^a   Wallace, Kris ^b   Evans, Andrew ^b   Toi, Ants ^b   Finelli, Antonio ^b   Jewett, Michael A S ^b   Fleshner, Neil ^b   Catton, Charles ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE SEED;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RISK; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NOMOGRAM; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84865470358     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.03.051     Document Type: Article

References (30)

1. A.J. Stephenson, M.W. Kattan, J.A. Eastham Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era J Clin Oncol 27 2009 274300 274305
2. P. Zhou, M.H. Chen, D. McLeod Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Clin Oncol 23 2005 6992 6998
3. L. Potters, M. Roach, B.J. Davis Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable Int J Radiat Oncol Biol Phys 76 2010 1061 1065
4. L. Potters, R. Purrazzella, S. Brustein The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 56 2003 749 754
5. A.V. D'Amico, A.A. Renshaw, L. Arsenault Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy Int J Radiat Oncol Biol Phys 45 1999 841 846
6. J.H. Pinthus, M. Witkos, N.E. Fleshner Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome J Urol 176 2006 979 984
7. D. Ash, A. Flynn, J. Battermann ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer Radiother Oncol 57 2000 315 321
8. B.J. Davis, E.M. Horwitz, W.R. Lee American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy Brachytherapy 11 2012 6 19
9. J. Crook, J. Borg, A. Evans 10-Year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients Int J Radiat Oncol Biol Phys 80 2011 1323 1329
10. G.S. Kulkarni, G. Lockwood, A. Evans Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy Cancer 109 2007 2432 2438
11. H. Lukka, P. Warde, T. Pickles Controversies in prostate cancer radiotherapy: consensus development Can J Urol 8 2001 1314 1322
12. M. Roach, G. Hanks, H. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. A. Hayden, W. Morris, M. Keyes The PSA value at 4-5 years after permanent prostate brachytherapy predicts for biochemical failure free survival Radiother Oncol 96 Suppl 2 2010 S2
14. R.G. Stock, T.J. Klein, J.A. Cesaretti Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy Int J Radiat Oncol Biol Phys 74 2009 753 758
15. F.A. Critz Time to achieve a prostate specific antigen nadir of 0.2 ng/ml after simultaneous irradiation for prostate cancer J Urol 168 2002 2434 2438
16. F.K. Chun, T. Steuber, A. Erbersdobler Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology Eur Urol 49 2006 820 826
17. U. Capitanio, P.I. Karakiewicz, C. Jeldres The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted Int J Urol 16 2009 526 529
18. V. Iremashvili, M. Manoharan, L. Pelaez Clinically significant Gleason sum upgrade: external validation and head-to-head comparison of the existing nomograms Cancer 118 2012 378 385
19. F.K. Chun, A. Briganti, S.F. Shariat Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation BJU Int 98 2006 329 334
20. U. Capitanio, P.I. Karakiewicz, L. Valiquette Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer Urology 73 2009 1087 1091
21. A.S. Moussa, M.W. Kattan, R. Berglund A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling BJU Int 105 2010 352 358
22. L. Budus, M. Graefen, G. Salomon The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy Int J Urol 17 2010 862 868
23. G.S. Kulkarni, R. Al-Azab, G. Lockwood Evidence for a biopsy derived grade artifact among larger prostate glands J Urol 175 2006 505 509
24. R.S. Turley, R.J. Hamilton, M.K. Terris Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database J Urol 179 2008 523 528
25. S.J. Freedland, W.B. Isaacs, E.A. Platz Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a SEARCH database study J Clin Oncol 23 2005 7546 7554
26. L. Klotz, L. Zhang, A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
27. W.J. Morris, M. Keyes, D. Palma Population-based study of biochemical and survival outcomes after permanent 125-I brachytherapy for low- and intermediate-risk prostate cancer Urology 73 2009 860 865
28. L. Potters, C. Morgenstern, E. Calugaru 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J Urol 173 2005 1562 1566
29. A.V. Taira, G.S. Merrick, W.M. Butler Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 79 2011 1336 1342
30. N.N. Stone, R.G. Stock, J.A. Cesaretti Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes Int J Radiat Oncol Biol Phys 76 2010 355 360